Premium
Poly(L‐Glutamic Acid)‐Drug Conjugates for Chemo‐ and Photodynamic Combination Therapy
Author(s) -
Yu Haiyang,
Bao Yanli,
Xu Caina,
Chen Li,
Tang Zhaohui
Publication year - 2021
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.202000192
Subject(s) - photodynamic therapy , chemistry , ethylene glycol , porphyrin , photosensitizer , tetraphenylporphyrin , drug delivery , nanoparticle , conjugate , drug carrier , singlet oxygen , glutamic acid , combinatorial chemistry , organic chemistry , materials science , nanotechnology , biochemistry , amino acid , oxygen , mathematical analysis , mathematics
Despite the polymeric vascular disrupting agent (poly( L ‐glutamic acid)‐ graft ‐methoxy poly(ethylene glycol)/combretastatin A4) nanoparticles can efficiently inhibit cancer growth, their further application is still a challenge owing to the tumor recurrence and metastasis after treatment. In this study, two poly( L ‐glutamic acid)‐drug conjugates for chemo‐and photodynamic combination therapy are fabricated. PLG‐ g ‐mPEG‐CA4 nanoparticles are prepared by combretastatin A4 (CA4) and poly( L ‐glutamic acid)‐ graft ‐methoxy poly(ethylene glycol) (PLG‐ g ‐mPEG) using the Yamaguchi esterification reaction. PLG‐ g ‐mPEG‐TPP (TPP: 5, 10, 15, 20‐tetraphenylporphyrin) nanoparticles are constructed using PLG‐ g ‐mPEG and amine porphyrin through condensation reaction between carboxyl group of PLG‐ g ‐mPEG and amino group of porphyrin. The results showed that PLG‐ g ‐mPEG‐CA4 nanoparticles have good antitumor ability. PLG‐ g ‐mPEG‐TPP nanoparticles can produce singlet oxygen under the laser irradiation. Moreover, the combined therapy of PLG‐ g ‐mPEG‐CA4 and PLG‐ g ‐mPEG‐TPP nanoparticles has higher antitumor effect than the single chemotherapy or the single photodynamic therapy in vitro. The combination of CA4 nondrug and photodynamic therapy provides a new insight for enhancing the tumor therapeutic effect with vascular disrupting agents and other therapy.